■ CorNeat Vision’s EverPatch, a synthetic tissue substitute, has been granted FDA 510(k) clearance. The company said that the patch, leveraging the novel EverMatrix material, is the first of its kind nondegradable tissue-integrating matrix for ophthalmic use. The non-woven, polymer matrix integrates with surrounding tissue and is intended to reinforce the sclera and help in the physical reconstruction of the ocular surface.

The company believes that the CorNeat EverPatch “is poised to displace the use of donor and processed tissue, commonly utilized in ocular surgeries but posing the risk of disease transmission.” The patch will have a limited US launch in Q3, expanding nationwide later. The company is also developing a synthetic cornea and a glaucoma drainage device.

“Our novel ophthalmic patch is significantly thinner than processed patch tissue, provides better handling as it does not ‘cheesewire’ when sutured, and has holes that allow for accurate positioning and anchoring,” said CMO and Co-founder Gilad Litvin, MD. “These holes also facilitate direct conjunctival adhesion to the sclera, thus supporting its bio-integration.”